ACRS Aclaris Therapeutics Inc.

5.55
+0.04  (+1%)
Previous Close 5.52
Open 5.53
Price To Book 1.07
Market Cap 229252867
Shares 41,269,643
Volume 339,800
Short Ratio
Av. Daily Volume 527,172

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2Q 2019.
ATI-502 (ATI-50002-AA-201) - dose ranging
Alopecia areata
Phase 2 open label 6-month data due 2Q 2019.
ATI-502 (VITI-201 Topical)
Vitiligo
Phase 2 trial ongoing.
ATI-502 AUATB-201 - open label
Alopecia areata - regrowth of eyebrows
Phase 2 data due 2H 2019.
ATI-501 (AUAT-201 Oral)
Alopecia areata
Approval announced December 15, 2017.
ESKATA (hydrogen peroxide)
Seborrheic keratosis (SK)
Phase 3 data due 2H 2019.
A-101 THWART-1 and THWART-2
Common warts (verruca vulgaris)
Phase 2 interim data released June 28, 2018.
ATI-502 AA-202 Topical - PK/safety
Alopecia areata
Phase 2 data due 2H 2019.
ATI-502 (ATI-50002-AGA-201) - open label
Androgenetic alopecia (AGA) - Hair loss
Phase 2 data due mid-2019.
ATI-502 (AD-201 Topical)
Atopic dermatitis (AD)

Latest News

  1. Consider These 3 Falling Knives
  2. Edited Transcript of ACRS earnings conference call or presentation 18-Mar-19 12:00pm GMT
  3. Aclaris Therapeutics to Attend Upcoming Investor Conference
  4. Aclaris Therapeutics, Inc. (ACRS) Q4 2018 Earnings Conference Call Transcript
  5. Aclaris: 4Q Earnings Snapshot
  6. Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
  7. Aclaris Therapeutics, Inc. to Host Earnings Call
  8. Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019
  9. Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg
  10. Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology
  11. Should You Worry About Aclaris Therapeutics, Inc.’s (NASDAQ:ACRS) CEO Salary Level?
  12. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  13. Do Hedge Funds Love Aclaris Therapeutics, Inc. (ACRS)?
  14. Aclaris Therapeutics Enters Oversold Territory
  15. Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
  16. Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials
  17. Top 6 Performing IPOs of 2015 (ONCE, GBT)
  18. Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan
  19. Aclaris Therapeutics (ACRS) Enters Oversold Territory